Program

The 12th Annual International Symposium on Liver & IBD Review Preliminary Program is available in the following formats:

View online Flipbook |Download/View PDF
Click here to register

Friday, January 18, 2019
6:30 pm – 10:30 pm Registration Open
Room:  Pre-Function Area
6:30 pm – 10:30 pm President’s Welcome Dinner
Room:  Whistler/Blackcomb
   
Saturday, January 19, 2019
INFLAMMATORY BOWEL DISEASE | AM SESSIONS (7:30 am – 10:00 am)
7:00 am – 9:00 am Breakfast
Room:  Whistler/Blackcomb
7:00 am – 11:00 am Registration Open
Room:  Pre-Function Area
7:30 am – 7:35 am Welcome and Opening Remarks
Room:  Mont Tremblant
Speaker: Dr. Imran Rasul

+/-

Imran Rasul, MD, FRCP(C)
Chair of the Endoscopy Unit
Credit Valley Hospital
President, OAG

Dr. Imran Rasul completed his undergraduate training at the University of Toronto in 1992. He went on to complete his Medical Degree, Internal Medicine and Gastroenterology training at the University of Toronto. Further training in Advanced Therapeutic Endoscopy was completed at University of Toronto. He has been practicing in Mississauga at the Credit Valley Hospital for the past seven years. Dr. Rasul has an interest in Advanced Endoscopy and is Chair of the Endoscopy Unit at Credit Valley Hospital.

7:35 am – 8:00 am Risk Stratification of the IBD Patient
Room:  Mont Tremblant
Speaker: Dr. Brian Feagan
denotes real or potential conflict of interest

+/-

Brian G. Feagan, MD, FRCP(C)
Professor of Medicine
Division of Gastroenterology
Departments of Medicine, Epidemiology and Biostatistics
Western University
Senior Scientific Officer, Robarts Clinical Trials Inc
London, Ontario, Canada

Brian G. Feagan completed a medical degree at the University of Western Ontario (Western University) in London, Ontario, Canada.  His postdoctoral training included residency in the Department of Medicine and a fellowship in Gastroenterology at the University of Western Ontario.

A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology, the College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada (CCC) and the European Crohn’s & Colitis Organization (ECCO).  He is the recipient of the 2013 Senior Achievement Award from the Crohn’s & Colitis Foundation of America (CCFA) and Dean’s Award of Excellence in 2013 from the University of Western Ontario. He has authored over 200 articles, book chapters and has also given over 900 invited presentations, at national and international scientific meetings. 

In 1997, Dr. Feagan became Director of Robarts Clinical Trials at the Robarts Research Institute, University of Western Ontario.  His research efforts focus on the design and implementation of randomized controlled trials of therapy for inflammatory bowel disease.  He has been the principal investigator on numerous large-scale randomized clinical trials.

8:00 am – 8:25 am Choosing the Right Drug for the Right Patient
Room:  Mont Tremblant
Speaker: Dr. Niels Vande Casteele
denotes real or potential conflict of interest

+/-

Niels Vande Casteele, PharmD, PhD
Assistant Professor at UC San Diego School of Medicine

Niels Vande Casteele, PharmD, PhD, is an Assistant Professor at UC San Diego School of Medicine.

Dr. Vande Casteele obtained his Bachelor in Pharmaceutical Sciences and Master in Drug Design and Development at the University of Leuven, Belgium. He performed research in the field of Molecular Biology at the Institute of Medical Sciences, University of Aberdeen, Scotland and in the field of Immunology at Sanquin, University of Amsterdam, the Netherlands. He obtained his Ph.D. in Pharmaceutical Sciences entitled “Optimizing anti-TNF therapy in inflammatory bowel disease patients, a step towards personalized dosing” at the University of Leuven, Belgium. After completing a postdoctoral fellowship, he was appointed as a faculty member of the School of Medicine at the University of California, San Diego. His research efforts focus on clinical pharmacology of biologics used in the treatment of chronic inflammatory diseases, with an emphasis on bioanalytical method development, therapeutic drug and immunogenicity monitoring in relation to treatment outcomes, and clinical drug development.

Dr. Vande Casteele also holds a position of Director, Precision Medicine at Robarts Clinical Trials, Inc. where he oversees the development, validation and operationalization of clinical and translational research tools to support sponsor- and investigator-initiated studies to ascertain efficient (early phase) drug development.

Dr. Vande Casteele has published over 70 peer reviewed research articles and book chapters, and has received awards for his research contributions from distinguished professional organizations such as the European Crohn’s and Colitis Organization (ECCO), the American Gastroenterological Association (AGA), the Belgian American Educational Foundation (BAEF), the Flemish Association of Gastroenterology and United European Gastroenterology (UEG) association.

Presentation Overview:
The medical management of inflammatory bowel disease (IBD) has been revolutionized over the past few decades by an expanding therapeutic armamentarium that now features several effective biologic agents and oral small molecules targeting different components of the immune response. Although these advances have afforded patients with Crohn’s disease (CD) and ulcerative colitis (UC) more treatment options than ever before, the role of optimizing drug therapy has also become increasingly important. The learning objectives for this talk are to:

  • Understand the mode of action of newer therapeutic agents for the treatment of moderate to severe CD and UC
  • Understand the variability in response to therapy and underlying mechanisms of mechanistic vs. pharmacokinetic failure
  • Gain insights into patient demographics and disease characteristics that can be used to stratify patients to the most effective therapy
8:25 am – 8:50 am Keeping the IBD Patient on Therapy Safe
Room:  Mont Tremblant
Speaker: Dr. Vivian Huang
denotes real or potential conflict of interest

+/-

Vivian Huang, MSc., MD, FRCP(C)
Assistant Professor and Clinician Investigator
Division of Gastroenterology, University of Toronto
Director, Preconception and Pregnancy in IBD clinical research program

Dr. Vivian Huang is an Assistant Professor of Medicine, in the Division of Gastroenterology, at the University of Toronto.  She completed medical school and Internal Medicine residency at Queen’s University, and Gastroenterology fellowship at the University of Toronto.  She obtained an Alberta Innovates Health Solutions clinician research fellowship to complete a 3-year Advanced IBD clinical research fellowship with a Masters of Science (Medicine) at the University of Alberta, where she initiated the Northern Alberta Preconception and Pregnancy in IBD clinical research program.  She returned to Toronto in October 2017 and is the Director of the Preconception and Pregnancy in IBD clinical research program at Mount Sinai Hospital, Toronto.   Her primary research interests focus on P4 (predictive, preventative, personalized, participatory) medicine, and include investigating the impact of maternal IBD on the fetus and neonate, improving patient and physician education and practice in IBD, and developing e-health strategies for improving health care.

Presentation Overview:
A review of recommendations for health maintenance and routine monitoring for IBD patients with medication specific considerations.

8:50 am – 9:05 am Panel Discussion 
Room:  Mont Tremblant
Moderator: Dr. Imran Rasul

+/-

Imran Rasul, MD, FRCP(C)
Chair of the Endoscopy Unit
Credit Valley Hospital
President, OAG

Dr. Imran Rasul completed his undergraduate training at the University of Toronto in 1992. He went on to complete his Medical Degree, Internal Medicine and Gastroenterology training at the University of Toronto. Further training in Advanced Therapeutic Endoscopy was completed at University of Toronto. He has been practicing in Mississauga at the Credit Valley Hospital for the past seven years. Dr. Rasul has an interest in Advanced Endoscopy and is Chair of the Endoscopy Unit at Credit Valley Hospital.


9:05 am – 9:20 am
9:20 am – 9:35 am
9:35 am – 9:45 am
DEBATE: Is it prime time for TDM?
Room:  Mont Tremblant
Speaker: PRO - Dr. Niels Vande Casteele
denotes real or potential conflict of interest
+/-

Niels Vande Casteele, PharmD, PhD
Assistant Professor at UC San Diego School of Medicine

Niels Vande Casteele, PharmD, PhD, is an Assistant Professor at UC San Diego School of Medicine.

Dr. Vande Casteele obtained his Bachelor in Pharmaceutical Sciences and Master in Drug Design and Development at the University of Leuven, Belgium. He performed research in the field of Molecular Biology at the Institute of Medical Sciences, University of Aberdeen, Scotland and in the field of Immunology at Sanquin, University of Amsterdam, the Netherlands. He obtained his Ph.D. in Pharmaceutical Sciences entitled “Optimizing anti-TNF therapy in inflammatory bowel disease patients, a step towards personalized dosing” at the University of Leuven, Belgium. After completing a postdoctoral fellowship, he was appointed as a faculty member of the School of Medicine at the University of California, San Diego. His research efforts focus on clinical pharmacology of biologics used in the treatment of chronic inflammatory diseases, with an emphasis on bioanalytical method development, therapeutic drug and immunogenicity monitoring in relation to treatment outcomes, and clinical drug development.

Dr. Vande Casteele also holds a position of Director, Precision Medicine at Robarts Clinical Trials, Inc. where he oversees the development, validation and operationalization of clinical and translational research tools to support sponsor- and investigator-initiated studies to ascertain efficient (early phase) drug development.

Dr. Vande Casteele has published over 70 peer reviewed research articles and book chapters, and has received awards for his research contributions from distinguished professional organizations such as the European Crohn’s and Colitis Organization (ECCO), the American Gastroenterological Association (AGA), the Belgian American Educational Foundation (BAEF), the Flemish Association of Gastroenterology and United European Gastroenterology (UEG) association.

Presentation Overview:
Although biologic agents are effective for the treatment of patients with Crohn’s disease (CD) and ulcerative colitis (UC), a substantial proportion of patients will experience either primary non-response or secondary loss of response to biologic therapy. The mechanisms of treatment failure are complex, including disease-related, drug-related, and patient-related factors. Given this complexity, treatment decisions directed by symptom assessment alone are unlikely to achieve optimal outcomes. Therapeutic drug monitoring (TDM) has emerged as a promising strategy to maximize treatment response in IBD. The learning objectives for this talk are to:

  • Understand inter-individual variability in drug exposure
  • Understand the drug exposure-response relationship
  • Understand when you should be doing TDM and in which patients

Speaker: CON - Dr. Brian Feagan
denotes real or potential conflict of interest
+/-

Brian G. Feagan, MD, FRCP(C)
Professor of Medicine
Division of Gastroenterology
Departments of Medicine, Epidemiology and Biostatistics
Western University
Senior Scientific Officer, Robarts Clinical Trials Inc
London, Ontario, Canada

Brian G. Feagan completed a medical degree at the University of Western Ontario (Western University) in London, Ontario, Canada.  His postdoctoral training included residency in the Department of Medicine and a fellowship in Gastroenterology at the University of Western Ontario.

A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology, the College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada (CCC) and the European Crohn’s & Colitis Organization (ECCO).  He is the recipient of the 2013 Senior Achievement Award from the Crohn’s & Colitis Foundation of America (CCFA) and Dean’s Award of Excellence in 2013 from the University of Western Ontario. He has authored over 200 articles, book chapters and has also given over 900 invited presentations, at national and international scientific meetings. 

In 1997, Dr. Feagan became Director of Robarts Clinical Trials at the Robarts Research Institute, University of Western Ontario.  His research efforts focus on the design and implementation of randomized controlled trials of therapy for inflammatory bowel disease.  He has been the principal investigator on numerous large-scale randomized clinical trials.


Rebuttal
9:45 am – 10:00 am Panel Discussion
Room:  Mont Tremblant
Moderator: Dr. Natasha Bollegala

+/-

Natasha Bollegala, Hon. BSc., MD, MSc, FRCP(C)
Gastroenterology, Women's College Hospital
Assistant Professor, Faculty of Medicine, University of Toronto

Natasha Bollegala completed an Honours Bachelor of Science at the University of Toronto with a specialist in Human Behaviour Biology and minor in Anthropology. She completed medical school at the University of Toronto (UofT) and went on to complete her internal medicine residency training at McMaster University. In 2012 she was awarded the Hamilton Health Sciences, Medical Staff Association, Outstanding Resident Award as well as the Chief Medical Resident Award. She returned to UofT as the inaugural resident of the gastroenterology residency training program – research stream. In 2014 she began a clinical and research Inflammatory Bowel Disease (IBD) fellowship at Mount Sinai Hospital, Toronto and was the recipient of the Ogden Goldstein Fellowship Award. She began an MSc in clinical epidemiology and healthcare research at UofT in 2014. She is a member of the Eliot Phillipson Clinician Scientist Training Program and the Clinician Investigator Program. In 2015, Natasha joined the Division of Gastroenterology at Women's College Hospital (WCH).

Dr. Bollegala has an interest in the area of quality improvement. She is a member of the WCH Quality Operations Committee, the Division of Gastroenterology Quality Improvement Committee and is active in the administration of the gastroenterology quality improvement residency curriculum. She is actively engaged in a number of research initiatives including studying the effects of an IBD transition nurse, a project funded by the Crohn's and Colitis Foundation of Canada. Her work utilizing health administrative data to explore health resource utilization in this area is funded through the Canadian Association of Gastroenterology.

 
10:00 am – 10:30 am Nutrition Break
Room:  Pre-Function Area
 
10:15 am – 10:30 am The Opportunities that GI Research in the Community Provide
Room:  Mont Tremblant
Speaker: Dr. Michael Gould

+/-

Michael Gould, MD, FRCP(C)
Assistant Professor, University of Toronto
President and Medical Director, Vaughan Endoscopy Clinic
Past President, Ontario Association of Gastroenterology

Dr. Michael Gould is the President and Medical Director of the Vaughan Endoscopy Clinic. He is Vice President and a partner in the Toronto Digestive Disease Associates (TDDA) clinical research group, which has participated in many GI clinical research trials. He is the interim Endoscopy Director at William Osler Health System.

Dr. Gould is a former Chief of Medicine of the William Osler Health System. He is a Past President and a founding member of the Ontario Association of Gastroenterology, and currently sits on the its Board of Directors. He is a board member of the Israel Cancer Research Fund . He was the CCO Endoscopy Lead from 2011- 2014, and helped design the Endoscopy QBP.

He has been a member of numerous colon screening guideline and quality committees at both the provincial and national levels.

Presentation Overview:
Clinical research, provides significant benefits to the researchers involved in the process,the clinicians caring for patients and  for the patients enrolled in the trials. Physicians in private practice play an important role in the development of new medications needed to treat disease and improve the health of patients. The large volume of new drugs, therapies and devices under development has dramatically increased the number of clinical trials required to properly evaluate them. This session will highlight the opportunities, benefits and challenges of GI research in the community with examples from our experience at TDDA.

10:30 am – 10:37 am Q & A
Room:  Mont Tremblant
10:37 am – 10:52 am Research in Motion: Mount Sinai Hospital
Room:  Mont Tremblant
Speaker: Dr. Adam Weizman

+/-

Adam V. Weizman, MD, MSc., FRCP(C)
Division of Gastroenterology
Mount Sinai Hospital
Assistant Professor of Medicine
University of Toronto

Dr. Weizman is a gastroenterologist at Mount Sinai Hospital in Toronto, Ontario and an Assistant Professor of Medicine at the University of Toronto. He received his medical degree from the University of Manitoba and subsequently did a Residency in Internal Medicine and Fellowship in Gastroenterology at the University of Toronto. He completed the Advanced Fellowship in Inflammatory Bowel Diseases at Cedars-Sinai Medical Center in Los Angeles, California and a Master's degree (MSc) in Quality Improvement and Patient Safety from the Institute of Health Policy, Evaluation, and Management at the University of Toronto.  His research interests include healthcare quality and health outcomes, with a focus on inflammatory bowel disease (IBD). Dr. Weizman is the Head of Quality and Patient Safety for the division of gastroenterology at Mount Sinai Hospital and the University Health Network.

Presentation Overview:
An update of the current research activities at Mount Sinai Hospital in inflammatory bowel disease will be reviewed.

10:52 am – 11:00 am Q & A
Room:  Mont Tremblant
 
11:00 am – 2:15 pm Extended Break
 
LIVER DISEASE | PM SESSIONS (3:00 pm – 5:00 pm)
2:15 pm – 5:00 pm Registration Open
Room:  Pre-Function Area
2:30 pm – 3:00 pm Nutrition Break
Room:  Pre-Function Area
 
3:00 pm – 3:25 pm Identifying the High-Risk Fatty Liver Patient
Room:  Mont Tremblant
Speaker: Dr. Supriya Joshi
denotes real or potential conflict of interest

+/-

Supriya Joshi,  MD, FRCP(C)
Gastroenterology & Hepatology
Credit Valley Hospital, Trillium Health Partners

After completing her Medical degree at the University of Western Ontario, Dr. Supriya Joshi completed her residency in Internal Medicine and Gastroenterology at The University of Toronto. Following completion of her GI Fellowship, she accepted a CIHR sponsored Fellowship in Hepatology at The University of Toronto with Dr. Jenny Heathcote. After working at Toronto Western Hospital as a clinical Hepatologist for a few years she has been working solely at The Credit Valley Hospital as a Gastroenterologist and Hepatologist since 2005. She has a special interest in autoimmune liver disease, viral hepatitis and fatty liver disease. She enjoys speaking and educating others on these topics, especially regarding the incoming volume of fatty liver disease and its management. She is an active member of Canadian Clinicians for Therapeutic Nutrition (CCTN) which is a group aiming to educate Canadians on whole food nutrition as therapy for the epidemic of nutrition induced chronic disease. Outside of medicine she is a mom to three young children and enjoys travel, hot yoga and a good HIT class.

3:25 pm - 3:50 pm Individualized Management of Autoimmune Liver Disease
Room:  Mont Tremblant
Speaker: Dr. Gideon Hirschfield
denotes real or potential conflict of interest

+/-

Gideon Hirschfield, MB BChir, PhD, FRCP (Lon)
Director, Autoimmune Liver Disease Programme
Toronto Centre for Liver Disease
Lily and Terry Horner Chair in Autoimmune Liver Disease Research

As the Lily and Terry Horner Chair in Autoimmune Liver Disease Research, Toronto Centre for Liver Disease/University of Toronto, and Honorary Professor, University of Birmingham, UK, my group seeks to understand, manage and treat patients with immune/inflammatory mediated liver disease rationally, personally and effectively. To do so we bridge discovery science, clinical trials and development of risk-stratified clinical care pathways, in a manner embedded in national and international networks (IAIHG; IPSCSG; Global PBC Study Group), and with strong interaction with Industry and patients. My programme and interest has arisen from pivotal discoveries, and subsequent collaborative research, focused on genetic risk factors for the development of autoimmune liver diseases (NEJM 2009; Nat Genet 2010; Nat Genet 2010; Nat Commun 2015), with laboratory science focusing on mechanistic understanding of risk pathways in human liver tissue studies (Gastroenterology 2014; Hepatology 2016; J Hepatol 2016; Gut 2016; J Autoimmune 2018; Hepatology Communications 2018). Utilising my strength in clinical Hepatology I have championed risk stratified care for patients (J Hepatol 2014; Gastroenterology 2014; Gastroenterology 2015; Gut 2016, Hepatology 2019) and built international credibility in delivery of clinical trials (Gastroenterology 2015; Hepatology 2016; NEJM 2016, J Hepatology 2019). My group continues to develop and implement a strong theme and belief in dissemination of knowledge to all, and evolving the use of quality metrics to ensure patients, and their families, are offered optimized, but research-driven, clinical management on a day-to-day basis.  The autoimmune liver disease programme at TGH now encompasses all aspects of care, pre- and post-transplant.

Presentation Overview:
Autoimmune liver diseases are rare and chronic inflammatory disorders of the liver and biliary tree.  Encompassing PBC, PSC, AIH and IgG4 associated sclerosing cholangitis, they are collectively impactful disorders that may be difficult to diagnose, are frequently accompanied by symptoms, and have a variable response to treatment.  The consequences of chronic inflammation can lead to end-stage liver disease and a need for liver transplantation, as well as a risk of developing malignancy of the liver and/or biliary tree.  Encompassing an individualised approach to looking after patients with autoimmune liver disease can optimise outcomes, and the approaches that can succeed in this regard focus on accurate diagnosis, individual risk stratification, early adoption of effective therapy and considered surveillance for complications of liver disease.

3:50 pm – 4:15 pm Personalized Management of Ascites and Encephalopathy
Room:  Mont Tremblant
Speaker: Dr. Cynthia Tsien
denotes real or potential conflict of interest

+/-

Cynthia Tsien, MD CM, MPH, FRCP(C)
Assistant professor, Department of Medicine
Division of Gastroenterology & Hepatology
University of Ottawa

Dr. Tsien obtained her medical degree from McGill University, where she also completed her internal medicine and gastroenterology residency training. Subsequently, she completed fellowships at the University of Toronto in general and transplant hepatology, with a focus on portal hypertensive complications of cirrhosis. This led to a research fellowship at the Cleveland Clinic focused on malnutrition in cirrhosis. She is currently an assistant professor at the University of Ottawa. Her main research interest is the diagnosis and treatment of sarcopenia (loss of muscle mass) in end-stage liver disease.  

Presentation Overview:
Ascites is a common complication of end-stage liver disease, and is associated with a 50% mortality over 2 years. Treatment of ascites includes dietary salt restriction, diuretics, and paracentesis. Management of hyponatremia in patients on diuretic therapy is controversial. For patients with moderate hyponatremia (serum sodium 121-125 mmol/L), consideration should be given to stopping diuretics and initiating volume expansion. For patients with ascites who are also on a non-selective beta-blocker (NSBB), the mean arterial pressure (MAP) should be monitored closely. A drop in MAP is indication for stopping NSBB. 

Hepatic encephalopathy (HE) is another portal hypertensive complication of cirrhosis that is associated with increased morbidity and mortality. HE is classified by disease severity, time course, and onset. Overt HE is treated with non-absorbable disaccharides and antibiotics (e.g. rifaximin). Adequate protein intake is important to maintain muscle mass, and branched-chain amino acids may be of benefit. Patients with refractory HE but preserved liver function should be evaluated for possible spontaneous portosystemic shunts. 

4:15 pm – 4:40 pm What to do when the patient doesn't fit the guidelines: Hepatitis C Management
Room:  Mont Tremblant
Speaker: Dr. Paul Marotta
denotes real or potential conflict of interest

+/-

Paul Marotta, MD, FRCP(C)
Associate Professor
University of Western Ontario
Transplant Hepatology and Gastroenterology,
Medical Director Liver Transplantation, Multiorgan Transplant Unit,
London Health Sciences Centre

Dr. Marotta has been an academic Hepatologist for over 20 yrs. He completed his Hepatology and Liver Transplant training at the Mayo Clinic in Rochester. He is the Medical Director of Liver Transplantation at the London Health Sciences Centre in London, Ontario as well as being the Program Director of the Advanced Hepatology/Liver Transplantation Fellowship Program.  Dr. Marotta is a past president of the Canadian Liver Transplant Network and remains a member of several national and international organizations.

Dr. Marotta has extensive publications in peer reviewed journals and remains involved in many clinical research protocols involving early and late phase clinical trials in several therapeutic areas including fatty liver disease (NASH), hepatitis C virus, hepatitis B, hepatocellular malignancy, cost effective analysis, autoimmune liver diseases and immunosuppression in liver transplant population.

4:40 pm – 5:00 pm Panel Discussion
Room:  Mont Tremblant
Moderator: Dr. Sapna Makhija

+/-

Sapna Makhija, MD, FRCP(C)
Gastroenterologist, GI Health Centre

Dr. Makhija is a gastroenterologist and one of the cofounders of Burlington’s G.I. Health Centre. She completed her doctorate of medicine at the University of Saskatchewan and then completed both her internal medicine and gastroenterology training at the University of Calgary. She then decided to make the move to the University of Toronto for a fellowship in clinical nutrition and obesity.

Dr. Makhija has now dedicated most of her time to managing and working at G.I. Health Centre. When not practising clinical medicine, she devotes time to various committees relating to her field, travels the globe, and gets involved in community fundraisers.

 
6:00 pm – 10:30 pm Children's Program
Room:  Mont Tremblant I
6:30 pm – 11:30 pm President's Canadiana Party
Room:  Whistler/Blackcomb
   
Sunday, January 20, 2019
7:15 am – 9:30 am Registration Open
Room:  Pre-Function Area
7:30 am – 9:30 am Breakfast
Room:  Whistler/Blackcomb
 
8:00 am – 9:30 am

Case Presentations & Expert Panel Discussion
Room:  Mont Tremblant
IBD: Dr. Neeraj Narula
denotes real or potential conflict of interest

Liver: Dr. Hemant Shah
denotes real or potential conflict of interest

Expert Panel:

  • Dr. Brian Feagan
    denotes real or potential conflict of interest
    +/-

    Brian G. Feagan, MD, FRCP(C)
    Professor of Medicine
    Division of Gastroenterology
    Departments of Medicine, Epidemiology and Biostatistics
    Western University
    Senior Scientific Officer, Robarts Clinical Trials Inc
    London, Ontario, Canada

    Brian G. Feagan completed a medical degree at the University of Western Ontario (Western University) in London, Ontario, Canada.  His postdoctoral training included residency in the Department of Medicine and a fellowship in Gastroenterology at the University of Western Ontario.

    A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology, the College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada (CCC) and the European Crohn’s & Colitis Organization (ECCO).  He is the recipient of the 2013 Senior Achievement Award from the Crohn’s & Colitis Foundation of America (CCFA) and Dean’s Award of Excellence in 2013 from the University of Western Ontario. He has authored over 200 articles, book chapters and has also given over 900 invited presentations, at national and international scientific meetings. 

    In 1997, Dr. Feagan became Director of Robarts Clinical Trials at the Robarts Research Institute, University of Western Ontario.  His research efforts focus on the design and implementation of randomized controlled trials of therapy for inflammatory bowel disease.  He has been the principal investigator on numerous large-scale randomized clinical trials.

  • Dr. Gideon Hirschfield
    denotes real or potential conflict of interest
    +/-

    Gideon Hirschfield, MB BChir, PhD, FRCP (Lon)
    Director, Autoimmune Liver Disease Programme
    Toronto Centre for Liver Disease
    Lily and Terry Horner Chair in Autoimmune Liver Disease Research

    As the Lily and Terry Horner Chair in Autoimmune Liver Disease Research, Toronto Centre for Liver Disease/University of Toronto, and Honorary Professor, University of Birmingham, UK, my group seeks to understand, manage and treat patients with immune/inflammatory mediated liver disease rationally, personally and effectively. To do so we bridge discovery science, clinical trials and development of risk-stratified clinical care pathways, in a manner embedded in national and international networks (IAIHG; IPSCSG; Global PBC Study Group), and with strong interaction with Industry and patients. My programme and interest has arisen from pivotal discoveries, and subsequent collaborative research, focused on genetic risk factors for the development of autoimmune liver diseases (NEJM 2009; Nat Genet 2010; Nat Genet 2010; Nat Commun 2015), with laboratory science focusing on mechanistic understanding of risk pathways in human liver tissue studies (Gastroenterology 2014; Hepatology 2016; J Hepatol 2016; Gut 2016; J Autoimmune 2018; Hepatology Communications 2018). Utilising my strength in clinical Hepatology I have championed risk stratified care for patients (J Hepatol 2014; Gastroenterology 2014; Gastroenterology 2015; Gut 2016, Hepatology 2019) and built international credibility in delivery of clinical trials (Gastroenterology 2015; Hepatology 2016; NEJM 2016, J Hepatology 2019). My group continues to develop and implement a strong theme and belief in dissemination of knowledge to all, and evolving the use of quality metrics to ensure patients, and their families, are offered optimized, but research-driven, clinical management on a day-to-day basis.  The autoimmune liver disease programme at TGH now encompasses all aspects of care, pre- and post-transplant.

  • Dr. Vivian Huang
    denotes real or potential conflict of interest
    +/-

    Vivian Huang, MSc., MD, FRCP(C)
    Assistant Professor and Clinician Investigator
    Division of Gastroenterology, University of Toronto
    Director, Preconception and Pregnancy in IBD clinical research program

    Dr. Vivian Huang is an Assistant Professor of Medicine, in the Division of Gastroenterology, at the University of Toronto.  She completed medical school and Internal Medicine residency at Queen’s University, and Gastroenterology fellowship at the University of Toronto.  She obtained an Alberta Innovates Health Solutions clinician research fellowship to complete a 3-year Advanced IBD clinical research fellowship with a Masters of Science (Medicine) at the University of Alberta, where she initiated the Northern Alberta Preconception and Pregnancy in IBD clinical research program.  She returned to Toronto in October 2017 and is the Director of the Preconception and Pregnancy in IBD clinical research program at Mount Sinai Hospital, Toronto.   Her primary research interests focus on P4 (predictive, preventative, personalized, participatory) medicine, and include investigating the impact of maternal IBD on the fetus and neonate, improving patient and physician education and practice in IBD, and developing e-health strategies for improving health care.

    Presentation Overview:
    A review of recommendations for health maintenance and routine monitoring for IBD patients with medication specific considerations.

  • Dr. Supriya Joshi
    denotes real or potential conflict of interest
    +/-

    Supriya Joshi,  MD, FRCP(C)
    Gastroenterology & Hepatology
    Credit Valley Hospital, Trillium Health Partners

    After completing her Medical degree at the University of Western Ontario, Dr. Supriya Joshi completed her residency in Internal Medicine and Gastroenterology at The University of Toronto. Following completion of her GI Fellowship, she accepted a CIHR sponsored Fellowship in Hepatology at The University of Toronto with Dr. Jenny Heathcote. After working at Toronto Western Hospital as a clinical Hepatologist for a few years she has been working solely at The Credit Valley Hospital as a Gastroenterologist and Hepatologist since 2005. She has a special interest in autoimmune liver disease, viral hepatitis and fatty liver disease. She enjoys speaking and educating others on these topics, especially regarding the incoming volume of fatty liver disease and its management. She is an active member of Canadian Clinicians for Therapeutic Nutrition (CCTN) which is a group aiming to educate Canadians on whole food nutrition as therapy for the epidemic of nutrition induced chronic disease. Outside of medicine she is a mom to three young children and enjoys travel, hot yoga and a good HIT class.

  • Dr. Paul Marotta
    denotes real or potential conflict of interest
    +/-

    Paul Marotta, MD, FRCP(C)
    Associate Professor
    University of Western Ontario
    Transplant Hepatology and Gastroenterology,
    Medical Director Liver Transplantation, Multiorgan Transplant Unit,
    London Health Sciences Centre

    Dr. Marotta has been an academic Hepatologist for over 20 yrs. He completed his Hepatology and Liver Transplant training at the Mayo Clinic in Rochester. He is the Medical Director of Liver Transplantation at the London Health Sciences Centre in London, Ontario as well as being the Program Director of the Advanced Hepatology/Liver Transplantation Fellowship Program.  Dr. Marotta is a past president of the Canadian Liver Transplant Network and remains a member of several national and international organizations.

    Dr. Marotta has extensive publications in peer reviewed journals and remains involved in many clinical research protocols involving early and late phase clinical trials in several therapeutic areas including fatty liver disease (NASH), hepatitis C virus, hepatitis B, hepatocellular malignancy, cost effective analysis, autoimmune liver diseases and immunosuppression in liver transplant population.

  • Dr. Neeraj Narula
    denotes real or potential conflict of interest
    +/-

    Neeraj Narula, MD, FRCP(C)
    Assistant Professor, McMaster University

    Dr. Neeraj Narula is the Director of the IBD Clinic at McMaster University and a Staff Gastroenterologist at Hamilton Health Sciences.  He completed the Present-Levison Advanced IBD fellowship at Mount Sinai Medical Centre in New York, NY, in 2015.  He trained to be a Chartered Accountant at the University of Waterloo and has worked at Ernst & Young and KPMG.  He subsequently attended medical school at the University of Alberta.  He completed his internal medicine residency and gastroenterology fellowship training at McMaster University. He also obtained a Masters in Public Health at Harvard T. H. Chan School of Public Health.  His research interests are predominantly in clinical epidemiology, nutrition, and pharmaceutical trials in IBD.

  • Dr. Hemant Shah
    denotes real or potential conflict of interest
    +/-

    Hemant Shah, MD, MScCH, HPTE, FRCP(C)
    Education Director, Francis Family Liver Clinic, Toronto Western Hospital
    Assistant Professor, University of Toronto
    Secretary, Ontario Association of Gastroenterology

    Dr. Hemant Shah is an Assistant Professor, Staff Hepatologist and Clinic Director at the Francis Family Liver Clinic, Toronto Western Hospital, University of Toronto. His clinical focus is viral liver disease and he maintains a busy teaching practice. In addition to clinical care, Dr. Shah is actively engaged in projects to develop innovative models of care for viral hepatitis, progress interprofessional collaboration and improve knowledge levels amongst primary care and specialty providers. He also serves as Program Director of the Hepatology Fellowship which trains three to five clinical and research fellows annually. Dr. Shah has graduate training in Health Practitioner Education. 

  • Dr. Cynthia Tsien
    denotes real or potential conflict of interest
    +/-

    Cynthia Tsien, MD CM, MPH, FRCP(C)
    Assistant professor, Department of Medicine
    Division of Gastroenterology & Hepatology
    University of Ottawa

    Dr. Tsien obtained her medical degree from McGill University, where she also completed her internal medicine and gastroenterology residency training. Subsequently, she completed fellowships at the University of Toronto in general and transplant hepatology, with a focus on portal hypertensive complications of cirrhosis. This led to a research fellowship at the Cleveland Clinic focused on malnutrition in cirrhosis. She is currently an assistant professor at the University of Ottawa. Her main research interest is the diagnosis and treatment of sarcopenia (loss of muscle mass) in end-stage liver disease.  

  • Dr. Niels Vande Casteele
    denotes real or potential conflict of interest
    +/-

    Niels Vande Casteele, PharmD, PhD
    Assistant Professor at UC San Diego School of Medicine

    Niels Vande Casteele, PharmD, PhD, is an Assistant Professor at UC San Diego School of Medicine.

    Dr. Vande Casteele obtained his Bachelor in Pharmaceutical Sciences and Master in Drug Design and Development at the University of Leuven, Belgium. He performed research in the field of Molecular Biology at the Institute of Medical Sciences, University of Aberdeen, Scotland and in the field of Immunology at Sanquin, University of Amsterdam, the Netherlands. He obtained his Ph.D. in Pharmaceutical Sciences entitled “Optimizing anti-TNF therapy in inflammatory bowel disease patients, a step towards personalized dosing” at the University of Leuven, Belgium. After completing a postdoctoral fellowship, he was appointed as a faculty member of the School of Medicine at the University of California, San Diego. His research efforts focus on clinical pharmacology of biologics used in the treatment of chronic inflammatory diseases, with an emphasis on bioanalytical method development, therapeutic drug and immunogenicity monitoring in relation to treatment outcomes, and clinical drug development.

    Dr. Vande Casteele also holds a position of Director, Precision Medicine at Robarts Clinical Trials, Inc. where he oversees the development, validation and operationalization of clinical and translational research tools to support sponsor- and investigator-initiated studies to ascertain efficient (early phase) drug development.

    Dr. Vande Casteele has published over 70 peer reviewed research articles and book chapters, and has received awards for his research contributions from distinguished professional organizations such as the European Crohn’s and Colitis Organization (ECCO), the American Gastroenterological Association (AGA), the Belgian American Educational Foundation (BAEF), the Flemish Association of Gastroenterology and United European Gastroenterology (UEG) association.

Expert Panel Discussion
Moderator: Dr. Hemant Shah

 
9:30 am - 9:35 am Closing Remarks
Room:  Mont Tremblant
Dr. David Morgan
denotes real or potential conflict of interest

+/-

David Morgan, MD, MSc., FRCP(C)
Head, Service of Gastroenterology
St. Joseph's Healthcare, Hamilton
Associate Professor, Division of Gastroenterology
McMaster University

Dr. David Morgan completed his undergraduate training in Human Genetics at McGill University. He did graduate studies including a Masters in Population Genetics. His undergraduate medical studies were completed at McMaster University and Post Graduate studies including Internal Medicine and Gastroenterology, were also completed at McMaster. Dr. Morgan took an additional fellowship year with special attention paid to advanced endoscopic techniques including YAG laser.

Dr. Morgan has published on topics such as GI Bleeding, Quality of Life in Cancer Care, Use of Proton Pump Inhibitors and The Prevention of Bleeding from GI Vascular Lesions. Dr. Morgan has participated on several CAG Consensus Panels dealing with such topics as CRC Screening. Dr. Morgan is a member of several international societies, is a Past President of the Canadian Association of Gastroenterology and is the current Vice President of the Ontario Association of Gastroenterology. Dr. Morgan is an Associate Editor for the ACP Journal Club and Evidence Based Medicine and has acted as a reviewer for many journals.

Dr. Morgan is on the Faculty at McMaster University and is involved in teaching at the undergraduate and post-graduate levels. He serves on many university and hospital committees. Dr. Morgan is Head of the Service of Gastroenterology and Deputy Chief of Medicine at St. Joseph's Hospital, Hamilton.

 


© 2019 Ontario Association of Gastroenterology
^